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Abstract 
Background 
Iron is vital for almost all living organisms by participating in a wide range of metabolic processes. 
However, iron concentration in body tissues must be tightly regulated since excessive iron may lead to 
microbial infections or cause tissue damage. Disorders of iron metabolism are among the most common 
human diseases and cover several conditions with varied clinical manifestations. 
Methods 
An extensive literature review on the basic aspects of iron metabolism was performed, and the most 
recent findings on this field were highlighted as well. 
Results 
New insights on iron metabolism have shed light into its real complexity, and its role in both healthy and 
pathological states has been recognized. Important discoveries about the iron regulatory machine and 
imbalances in its regulation have been made, which may lead in a near future to the development of new 
therapeutic strategies against iron disorders. Besides, the toxicity of free iron and its association with 
several pathologies has been addressed, although it requires further investigations. 
Conclusion 
This review will provide students in the fields of biochemistry and health sciences a brief and clear 
overview of iron physiology and toxicity, as well as imbalances in the iron homeostasis and associated 
pathological conditions. 
CHEMICAL PROPERTIES AND BIOLOGICAL FUNCTIONS OF IRON 
Iron is a part of the subfamily of transition elements and is one of the most abundant metals on Earth, as 
well as an essential nutrient. It is a component of several metalloproteins and plays a vital function in 
essential biochemical activities, such as oxygen sensing and transport, electron transfer, and catalysis. 
This unique ability of iron to serve as an electron donor and acceptor renders this metal irreplaceable and 
indispensable for life. Iron exists in two steady oxidative states: ferrous (Fe2+) and ferric (Fe3+). In aqueous 
media, Fe2+ is spontaneously oxidized by molecular oxygen to Fe3+ to form ferric hydroxide (Fe(OH)3). 
Therefore, the maximal solubility of iron in an oxidative environment like extracellular fluids is limited by 
the product solubility constant of Fe(OH)3. At pH 7.0, the maximal solubility of Fe3+ is very low, whereas 
Fe2+ solubility is much higher. On the other hand, when the absorbed iron is not bound to proteins, it is 
capable of catalyzing reactions that produce harmful free radicals (refer to Toxicity of iron). As a result of 
the toxicity of free iron and its low solubility in the presence of oxygen and neutral pH conditions, 
organisms have been forced to develop proteins (e.g., transferrin) that are able to bind Fe3+ and maintain 
its stable form but, simultaneously, make it available for biological processes. Moreover, the poor 
solubility of iron is an important chemical property since it renders iron difficult to access by pathogenic 
microorganisms, thus avoiding their proliferation. 
The majority of iron is intracellular, sequestered within the iron storage proteins (ferritin and 
hemosiderin) or associated with proteins in the form of heme, which is a common prosthetic group 
composed of protoporphyrin IX and a Fe2+ ion. The insertion of Fe2+ into protoporphyrin IX, catalyzed by 
ferrochelatase in the mitochondria, determines the final step of the heme biosynthetic pathway. 
Subsequently, heme is exported to the cytosol for incorporation into hemoproteins. The microsomal 
heme oxygenases 1 (HO-1), 2 (HO-2), and 3 (HO-3) catalyze heme degradation. The released Fe2+ is 
reutilized. This reaction also generates carbon monoxide (CO), which is thought to be involved in signaling 
pathways, and biliverdin, which is further enzymatically converted to the antioxidant bilirubin. 
The most abundant mammalian hemeproteins, hemoglobin and myoglobin, serve as oxygen carriers in 
the erythroid tissue and in the muscle, respectively. Oxygen binding is mediated by the heme moieties. 
Another important class of hemeproteins are cytochromes, which play an important function in redox 
reactions and electron transport. 
Iron–sulfur clusters (e.g., 2Fe-2S, 3Fe-4S, or 4Fe-4S) are the most prevalent forms of nonheme iron in 
metalloproteins. They play a wide range of functional roles, such as electron transfer (e.g., the Rieske 
proteins in complex III of the respiratory chain), structural stabilization (bacterial endonuclease III), 
transcriptional regulation (the bacterial SoxR and FNR transcription factors), and catalysis (e.g., aconitase, 
an enzyme of the citric acid cycle). Other forms of protein-associated iron may include iron-oxo clusters 
(e.g., in ribonucleotide reductase, an enzyme required for DNA synthesis) or mononuclear iron centers 
(e.g., in cyclooxygenase and lipoxygenase, enzymes involved in inflammatory responses). 
It is also known that nonheme iron plays an important role in a mechanism for oxygen sensing, via the 
hypoxia-inducible factor (HIF). Under normoxic conditions, HIF undergoes hydroxylation that makes it 
rapidly degraded via the ubiquitin-proteasome pathway, in a process catalyzed by iron-dependent 
enzymes. On the other hand, under hypoxic conditions, HIF is stabilized and allows the activation of genes 
involved in angiogenesis, glycolysis, cell proliferation and survival, and erythropoiesis. This process is of 
extreme importance to cellular adaptation to low oxygen conditions. 
BODY IRON HOMEOSTASIS 
Iron Distribution in the Human Body 
The adult human body contains approximately 3–5 g of iron (45–55 mg/kg of body weight in adult women 
and men, respectively), with more than two-thirds (∼2 g) incorporated in the hemoglobin of developing 
erythroid precursors and mature red blood cells. The remaining body iron is mostly found in a transit pool 
in reticuloendothelial macrophages (∼600 mg) or stored in hepatocytes (∼1000 mg) within ferritin, an 
iron storage protein. A smaller fraction is found in muscles within myoglobin (∼300 mg), while only a 
minuscule amount (∼8 mg) is constituent of other cellular iron containing proteins and enzymes. A healthy 
individual absorbs daily 1–2 mg of iron from the diet, which compensates nonspecific iron losses by cell 
desquamation in the skin and the intestine (Fig. 1). Furthermore, menstruating women physiologically 
lose iron from the blood. Recycling of iron via reticuloendothelial macrophages provides the amount of 
iron required for erythropoiesis (30 mg/day). Iron bound to plasma transferrin corresponds to less than 
0.1% of total body iron, but represents, in kinetic terms, the most active pool. 
 
 
Iron Absorption 
Dietary iron absorption occurs mostly at the duodenum and the upper portions of the jejunum. The body 
has no effective means of excreting iron and thus the regulation of absorption of dietary iron plays a 
critical role in iron homeostasis. Multiple steps are involved in iron absorption, including the reduction of 
iron to a ferrous state, apical uptake, intracellular storage or transcellular trafficking, and basolateral 
release. Dietary iron is found in heme (10%) and nonheme (90%) forms and their absorption occurs under 
different mechanisms. 
Absorption of dietary nonheme iron involves the release of elemental iron from digested food and its 
maintenance in a soluble form, which is accomplished in part by gastric acid. The low pH of the gastric 
effluent dissolves ingested inorganic iron and facilitates its enzymatic reduction (Fe3+ is reduced to Fe2+ by 
ferric reductases present on the apical surface of duodenal enterocytes). Then, iron is transported across 
the intestinal epithelium by a transporter called divalent metal transporter 1 (DMT-1), which also traffics 
other metal ions such as copper, zinc, and cobalt by a proton-coupled mechanism. 
Heme iron is absorbed into the enterocytes by a putative, not completely identified, heme carrier protein 
1, a membrane protein found in the proximal intestine, where heme absorption is greater. Once 
internalized in the enterocytes, it is likely that most dietary heme iron is metabolized by heme oxygenase 
to release Fe2+, which enters a common pathway with dietary nonheme iron before it leaves the 
enterocytes. Nevertheless, it remains uncertain whether some intact heme iron crosses the cell, leaving 
the enterocyte through the action of the recently characterized heme exporters. These exporters are also 
expressed in liver, kidney, and erythroblast, suggesting that they may act at those sites. 
Once inside the intestinal epithelial cell, iron is exported across the basolateral membrane of the 
enterocyte into the circulation (absorbed iron), where it binds to transferrin, a potent chelator, able of 
binding iron tightly but reversibly, and is transported to sites of use and storage. Transferrin-bound iron 
enters target cells (erythroid, immune, and hepatic cells) through a process of receptor-mediated 
endocytosis. Senescent erythrocytes undergo phagocytosis by reticuloendothelial system (RES) 
macrophages, heme iron is metabolized by heme-oxygenase, and iron is stored as ferritin (the major iron 
storage protein). Later, iron is released from macrophages and bound by transferrin, which transports 
iron to the bone marrow. This internal turnover of iron is essential to meet the requirements for 
erythropoiesis. 
Basolateral iron transport is mediated by ferroportin 1 and then iron is oxidized by a multicopper oxidase 
protein called hephaestin (an enzymatic protein similar to plasma ceruloplasmin) before being bound by 
plasma transferrin. The absorption of iron is dependent on the body iron stores, hypoxia, and rate of 
erythropoiesis. 
 
MAINTENANCE OF IRON HOMEOSTASIS 
 
Since iron is required for a number of diverse cellular functions, a constant balance between iron uptake, 
transport, storage, and utilization is required to maintain iron homeostasis. 
Mammals regulated systemic iron stores at the level of intestinal absorption, although iron elimination 
from the body is not regulated and is entirely dependent upon physiological and nonphysiological blood 
and epithelial cell loss. It is believed that three regulatory signals contribute to the maintenance of 
homeostasis. First signal is called “dietary regulator”—after the ingestion of a dietary iron bolus, 
absorptive enterocytes are resistant in acquiring additional iron for several days. This probably results 
from the accumulation of intracellular iron because high intracellular iron may suppress the expression of 
DMT1. The second signal, called “stores regulator,” controls iron uptake in response to body iron stores. 
In iron-deficient conditions, iron absorption is significantly stimulated by two- to threefold. When iron 
stores are replenished, iron absorption returns to basal levels. Third signal is called “erythropoietic 
regulator” and modulates iron absorption in response to erythropoiesis. This signal has a dominant role 
in the control of iron homeostasis and has a great capacity to increase iron absorption because most of 
the body iron is utilized by the bone marrow for hemoglobinization of red blood cells. 
More recently, two models have been proposed to explain how the absorption of iron is regulated: the 
crypt programming model and the hepcidin model. The first one proposes that enterocytes in the crypts 
of the duodenum take up iron from the plasma. The intracellular iron level of the crypt cells corresponds 
to the body iron stores, which in turn determines the amount of iron absorbed from the gut lumen. The 
crypt cells express both transferrin receptor 1 (TfR1) and TfR2, which mediate the cellular uptake of 
transferrin-bound iron from plasma. The hepcidin model suggests that hepcidin is secreted into the blood 
and interacts with villous enterocytes to regulate the rate of iron absorption. Hepcidin is a circulating 
regulatory hormone peptide produced by hepatocytes that functions as the master regulator of cellular 
iron export by controlling the amount of ferroportin (the iron exporter present on the basolateral surface 
of intestinal enterocytes and macrophages). The binding of hepcidin to ferroportin induces ferroportin 
internalization and degradation, resulting in cellular iron retention and decreased iron export. It is 
hypothesized that when hepcidin levels are reduced, as in iron deficiency (ID), ferroportin 1 expression 
and iron release from intestinal cells, liver, and cells of RES are increased. On the other hand, when 
hepcidin levels are increased, as in iron overload (by the uptake of transferrin-bound iron) or 
inflammation, iron release from intestinal crypt cells, liver, and macrophages is reduced. 
Currently, there are evidences to support both models and it is possible that both control mechanisms 
involved in the regulation of iron homeostasis. 
IRON AND INFECTION 
Iron is an indispensable nutrient in the life of several organisms, including bacteria. Bacteria require iron 
and other transition metals so that they can replicate, and eventually cause disease. Therefore, the 
withholding of iron is an effective strategy of the host in the prevention of infection, a process commonly 
referred as nutritional immunity. As previously stated, the poor solubility of iron is an important chemical 
property in this context. Nevertheless, there are some iron-binding proteins that maintain low levels of 
free, circulating iron, as well as hinder the uptake of iron by bacteria, including transferrin, lactoferrin, 
and siderocalin. 
Both transferrin and lactoferrin have great affinity for iron. Moreover, most of the iron-binding sites of 
these proteins are normally unoccupied, thus making the amount of free iron very small to support 
bacterial growth. Therefore, the antimicrobial properties of these two proteins were solely attributed to 
their ability to sequester iron. However, and in the case of lactoferrin, new insights emerged regarding to 
its antimicrobial properties. It is now well established that lactoferrin possesses bactericidal activity 
against a wide range of microorganisms. Nevertheless, these bactericidal properties appear to be iron 
independent and are probably a result of a direct interaction of lactoferrin with bacterial surface. 
Receptors for the N-terminal region of lactoferrin have been discovered on the surface of some 
microorganisms. It is thought that lactoferrin binds to these receptors by inducing cell death in Gram-
negative bacteria. On the other hand, the bactericidal activity of lactoferrin in Gram-positive bacteria 
seems to be mediated by electrostatic interactions between the negatively charged lipid layer and the 
positively charged lactoferrin surface that cause changes in the permeability of the bacterial membrane. 
Siderocalin (also known as neutrophil gelatinase-associated lipocalin (NGAL) or lipocalin 2) is a member 
of the lipocalin family of binding proteins. During infection, bacteria secrete iron chelating compounds 
called siderophores, which allow the uptake of iron from the host. Siderocalin is released by neutrophils 
at sites of infection and inflammation, and blocks bacterial proliferation through binding to bacterial 
siderophores, which prevents iron uptake by bacteria. 
IMBALANCE OF IRON HOMEOSTASIS 
The imbalance of iron homeostasis is associated with the development of several diseases. For instance, 
iron can be toxic and damaging when it is in excess and accumulates in different human organs. This 
excess iron in the body is usually associated with some iron-overloading disorders, such as hereditary 
hemochromatosis (HH) and thalassemias. On the other hand, low levels of iron in the right place could 
lead, for example, to the development of ID anemia (IDA). Therefore, a proper balance of iron 
concentration must be achieved. 
Toxicity of Iron 
Although iron is indispensable for life, its excess can be toxic to tissues. Iron has the ability to produce 
oxygen free radicals under aerobic conditions, which turns it into a potential harmful component. 
Free radicals are generated within the cell as part of normal cellular mechanisms. However, the 
overproduction of reactive oxygen species (ROS), such as superoxide (•O2−) and hydroxyl (•OH) radicals 
may lead to cellular damage. When iron exceeds the metabolic needs of the cell, it can generate oxidative 
stress, characterized by an increase in the basal concentration of ROS. The reactions between iron and 
ROS are shown in Figure 2. 
 
 
Generally, the main sources of OH radicals are Fenton and Harber–Weiss reactions. In relation with •O2−, 
this radical has an extremely short half-life and rapidly undergoes dismutation, yielding hydrogen 
peroxide (H2O2). In biological systems living under aerobic conditions, OH radicals are formed from oxygen 
as a result of both normal cellular metabolism and oxidative stress associated with several conditions 
(e.g., inflammation, platelet aggregation, etc.). These radicals are the most reactive free radical species 
known and have the capacity to react with a wide range of cellular components, such as DNA, proteins, 
and cell membranes. The resulting effects are impaired synthesis of proteins, membrane lipids, and 
carbohydrates; induction of proteases; and altered cell proliferation. 
In the last few years, several studies have shown a relationship between free radicals and the 
development of certain conditions, such as cancer, diabetes, cardiovascular, neurodegenerative and 
ophthalmologic diseases, and aging. In diseases of iron overload (e.g., HH), the generation of free radicals 
leads to tissue damage and organ failure. Moreover, excess of free iron has been considered carcinogenic, 
once the generation of free radicals by this metal can promote DNA strand breaks, oncogenes activation, 
and tumor suppressor genes inhibition. More recently, the role of iron in neurodegenerative disorders 
such as Parkinson's and Alzheimer's diseases has been the target of intensive study, since it has been 
suggested that iron overload increases brain oxidative stress status. 
ID Diseases 
ID is defined as the reduction of the total iron content of the body, and results when iron losses or 
requirements exceed its absorption. ID is the most common nutritional deficiency and the leading cause 
of anemia worldwide, remaining as one of the most important public health issues. 
ID can result from several causes, which are normally classified into two categories: increased iron needs 
and decreased iron intake or absorption (Table 1). 
 
 
ID anemia 
ID is usually seen as a continuous process, comprising three elementary steps: iron depletion, iron-
deficient erythropoiesis (IDE), and IDA. Basically, IDA occurs when ID is sufficiently severe to the point of 
reducing erythropoiesis. IDA is the most frequent type of chronic anemia. Iron is an essential mineral for 
several metabolic reactions in our body. IDA is associated with several conditions, such as preterm 
delivery, defects in cognitive and psychomotor development, impaired work capacity, diminished growth, 
alterations in bone mineralization, and diminished immune response. Furthermore, increased oxidative 
stress in patients with IDA has been reported. Iron is an essential cofactor for enzymes involved in several 
cellular processes, namely in antioxidant metabolism. Therefore, the increased oxidative stress, and 
consequent DNA damage, seems to play a critical role in the pathogenesis of IDA. 
Iron Overload Diseases 
Iron overload could be defined as an excess of iron in the body, regardless of the presence or absence of 
tissue damage. However, progressive accumulation of iron in vital organs increases the risk of hepatic, 
cardiovascular, and pancreatic dysfunctions. Moreover, and in line with previously discussed, individuals 
with iron overload diseases have an increased susceptibility to infectious diseases. 
Iron overload is commonly classified into two categories: primary (or hereditary) and secondary (or 
acquired) (Table 2). Primary iron overload is the result of an inherited defect in the regulation of iron 
balance, whereas secondary iron overload is almost always the consequence of other genetic or acquired 
disorders. 
 
 
Primary iron overload 
The classical example of primary iron overload is HH. HH is a common genetic disorder among Caucasian 
population, with an autosomal recessive inheritance, and is characterized by an excessive absorption of 
dietary iron. Excess iron progressively accumulates in different organs, particularly in liver, heart, and 
pancreas. The common complications are cirrhosis and carcinoma of the liver, cardiomyopathy, diabetes 
mellitus, and if not treated, death. 
HH occurs in patients with mutations in specific genes involved in iron metabolism (e.g., HFE gene), and 
has been classified into four subtypes (types 1, 2, 3, and 4). The majority of patients (approximately 85–
90%) have type 1, which is associated with mutations in HFE gene (OMIM 235200). This gene is located 
on the short arm of chromosome 6 (6p21.3) and encodes for a transmembrane protein. This protein 
associates with β-2-microglobulin and regulates the interaction between transferrin and its receptor 
(Fig. 3). Two missense mutations in this gene were identified: C282Y (C, cysteine replaced by Y, tyrosine) 
and H63D (H, histamine replaced by D, aspartic acid). Although the whole mechanism leading to iron 
overload remains to be elucidated, there are evidences that it could also arise from hepcidin 
dysregulation. 
  
On the other hand, mutations of other genes coding for iron regulatory proteins (ferroportin, 
hemojuvelin, hepcidin, and TfR 2) have been implicated in primary iron overload diseases, accounting for 
most of the non-HFE forms of HH, such as juvenile hemochromatosis or ferroportin disease. 
Secondary iron overload 
Secondary iron overload typically occurs as a result of a wide range of conditions, namely ineffective 
erythropoiesis, chronic liver diseases, parenteral administration, or ingestion of excessive amounts of 
iron. 
One of the best studied examples of iron overload secondary to ineffective erythropoiesis and blood 
transfusions is thalassemia. Thalassemia involves a group of recessively inherited defects in the synthesis 
of globin chains of hemoglobin. The two major forms of the disease are α-thalassemia (defect in the 
production of α-globin chain) and β-thalassemia (defect in the production of β-globin chain). Thalassemia 
is characterized by chronic anemia as a result of ineffective erythropoiesis, and a variety of secondary 
complications such as iron overload. This complication is particularly severe in β-thalassemia, and has 
become a leading cause of morbidity and mortality among thalassemic patients. Moreover, the standard 
treatment is chronic blood transfusion to increase the hemoglobin levels. Initially, it was thought that iron 
overload in these patients was exclusively caused by this therapeutic procedure. However, it is known 
that thalassemic patients have increased gastrointestinal iron absorption (three to four times greater than 
normal), as a consequence of ineffective erythropoiesis. This process is mediated by downregulation of 
hepcidin and upregulation of ferroportin, which together with chronic transfusion therapy seriously 
aggravate the clinical setting of the patients. 
The treatment of some diseases, such as thalassemia (previously described) or myelodysplastic 
syndromes is based on repeated blood transfusions. Although this procedure allows the suppression of 
endogenous erythropoiesis and the correction of the anemia, chronic transfusion therapy remains one of 
the most important cause of secondary iron overload. Our body is not capable to remove excess iron, thus 
repeated transfusion can rapidly result in iron overload. Each unit of packed red blood cells contains about 
200–250 mg of iron. For instance, a treatment program with 100 units involves loading with 20 g of iron, 
an amount five to six times greater than the normal content in the organism (3–5 g). In order to overcome 
this problem, in the last few years, iron-chelating therapy has been used for patients with transfusional 
iron overload. 
CONCLUSIONS 
In the last few decades, several studies concerning iron metabolism have been carried out. Although it 
seems to be a simple process, new insights on iron metabolism have allowed the perception of its real 
complexity. The extreme importance of iron in almost all living organisms, including humans, and its role 
in healthy and pathological conditions has now been recognized. 
Although iron plays an important function in several biochemical processes, its concentration in body 
tissues needs to be tightly and constantly regulated. Important discoveries about this complex regulatory 
machinery have been made in the past few years. On the other hand, and taking into account that 
disorders of iron metabolism are among the most common human diseases, imbalances in this regulatory 
mechanism and associated complications have also been the target of intensive investigations. 
However, there is a wide range of aspects in this field that needs further elucidation. For instance, a 
detailed understanding of the molecular mechanisms involved in iron absorption and metabolism might 
be the key to the development of novel therapeutic strategies in iron overload and ID diseases. Moreover, 
the toxicity of free iron and its association with the development of some pathological conditions, 
especially neurodegenerative and malignant diseases, require further investigations. 
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